N4 Pharma PLC Covid-19 Project Update (1420O)
28 Mayo 2020 - 01:00AM
UK Regulatory
TIDMN4P
RNS Number : 1420O
N4 Pharma PLC
28 May 2020
28 May 2020
N4 Pharma plc
("N4 Pharma", the "Company" or the "Group")
Covid-19 Project Update
Further to the Company's announcement on 16 April 2020, N4
Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, is pleased to provide an update on the progress of
its Covid-19 proof of concept work for Nuvec(R).
As previously announced, the Company appointed Evotec
International Gmbh ("Evotec") to undertake the Nuvec(R) proof of
concept work. The Company can confirm that the first phase of the
project has been carried out, within the expected timeframe, and
that the plasmid DNA has been successfully amplified to produce
sufficient material for the rest of the project and has been tested
to confirm it matches the required specification. Evotec has also
used this batch of the plasmid DNA to express the Covid-19 spike
protein to be used as a positive control for the studies. Evotec
will now move to the second phase of the work and start the
in-vitro testing of Nuvec(R) as planned, during the first week of
June 2020. This phase is expected to last approximately ten
weeks.
The third phase of the in-vivo protein expression testing will
be to undertake an initial pre in-vivo study to demonstrate
expression of the spike protein in target cells in a murine target.
Following the recent fundraise, announced on 13 May 2020, the
Company is now also exploring ways in which it can bring forward
the start of certain areas of this third phase to run alongside the
in-vitro work.
Enquiries:
N4 Pharma Plc Via Scott PR
Nigel Theobald, CEO
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Asha Chotai
Turner Pope Investments (TPI) Ltd Tel: +44(0)20 3657 0050
Andrew Thacker
Scott PR Tel: +44(0)1477 539 539
Georgia Smith
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for cancer and vaccine treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for cancer and vaccine treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
UPDGZGZKGNRGGZZ
(END) Dow Jones Newswires
May 28, 2020 02:00 ET (06:00 GMT)
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
N4 Pharma (LSE:N4P)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024